Commentary: High-Dose Olanzapine for Treatment-Resistant Schizophrenia
J Clin Psychiatry 2008;69(2):176-177
© Copyright 2014 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Because this piece has no abstract, we have provided for your benefit the first 3 sentences of the full text.
In this issue of the Journal
, Meltzer et al.1
provocative results from a randomized, double-blind I
study showing that larger-than-typically-prescribed doses
of olanzapine appear to be equivalent to conventional
doses of clozapine in treatment-resistant schizophrenia.
Although the sample size is relatively small (total
N = 40), the data are consistent with the notion that highdose
olanzapine might be effective in treatment-resistant
schizophrenia. These findings are important because they
open up the possibility of a new approach to treatmentresistant